Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T14:16:50.853Z.
Calculation as of: 2026-10-06T14:16:50.853Z.
Quote observation: 2026-10-06T14:15:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8e2f3ec51e074b036058196f7f903a3cac1545bb57f25a27b7ce4fd0c255fbf9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Galectin Therapeutics Inc.
Market Cap
$237.74M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$236.07M
Price/FCF Ratio
5.88
TTM Avg
7.87
3Y Avg
7.87
5Y Avg
7.87
Market Cap
$244.25M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$243.81M
Price/FCF Ratio
N/A
TTM Avg
780.39
3Y Avg
474.08
5Y Avg
244.04
Market Cap
$244.11M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Galectin Therapeutics Inc. (GALT) | $237.74M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $236.31M | N/A | N/A | N/A | N/A |
| High Tide Inc. (HITI)vs › | $240.76M | 20.99 | 18.26 | 16.59 | 17.78 |
| Akebia Therapeutics, Inc. (AKBA)vs › | $236.07M | 5.88 | 7.87 | 7.87 | 7.87 |
| InflaRx N.V. (IFRX)vs › | $241.56M | N/A | N/A | N/A | N/A |
| BioAge Labs Inc. (BIOA)vs › | $234.82M | N/A | N/A | N/A | N/A |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $244.25M | N/A | N/A | N/A | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.81M | N/A | 780.39 | 474.08 | 244.04 |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $244.11M | N/A | N/A | N/A | N/A |
| MacroGenics, Inc. (MGNX)vs › | $231.69M | N/A | 99.21 | 99.21 | 99.21 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
